54 Trials found, please click on a trial for more information
Protocol Title
Protocol Number / Cancer Type
A Clinical Trial to Determine the Efficacy of Five Years of Letrozole Compared to Placebo in Patients Completing Five Years of Hormonal Therapy Consisting of an Aromatase Inhibitor (AI) or Tamoxifen Followed by an AI in Prolonging Disease-Free Survival in Postmenopausal Women with Hormone Receptor Positive Breast Cancer
Offered at: Providence Cancer Institute
B-42 / Breast Cancer
A double-blind phase III trial of doxorubicin and cyclophosphamide followed by paclitaxel with bevacizumab or placebo in patients with lymph node positive and high risk lymp node negative breast cancer.
Offered at: Providence Cancer Institute
E5103 / Breast Cancer
A Multi-center, Open-label, Randomized, Phase II Clinical Trial Evaluating Safty and Efficacy of FOLFIRI with Either panitumumab or Bevacizumab as Second-line Treatment in Subjects with Metastatic Colorectal Cancer.
Offered at: Providence Cancer Institute
SPIRITT / Gastrointestinal
A Multinational, Randomized, Double-Blind Study Comparing Aflibercept Versus Placebo in Patients Treated with Second-Line Docetaxel after Failure of One Platinum Based Therapy for Locally Advanced or Metastatic Non-Small-Cell Lung Cancer
Offered at: Providence Cancer Institute
EFC10261 ( VITAL) / Lung Non-Small Cell
A Phase 2 Randomized, Placebo-Controlled, Double-Blind Study of the Efficacy of MORAb-009 in Combination with Gemcitabine in Patients with Advanced Pancreatic Cancer
Offered at: Providence Cancer Institute
MORAB-009-002 / Gastrointestinal
A Phase II Study of Lenalidomide (REVLIMID, NSC-703831) for Previously Untreated Non-M3, Deletion 5Q Acute Myeloid Leukemia (AML) in Patients Age 60 or Older Who Decline Remission Induction Chemotherapy
Offered at: Providence Cancer Institute
SWOG 0605 / Leukemia
A Phase II Study of VELCADE (Bortezomib) in Combination With Bendamustine and Rituximab in Subjects With Relapsed or Refractory Follicular Lymphoma
Offered at: Providence Cancer Institute
C05011 (VERTICAL) / Lymphoma
A phase III clinical trial comparing trastuzumab given concurrently with radiation therapy and radiation therapy alone for women with HER2-positive ductal carcinoma in situ resected by lumpectomy.
Offered at: Providence Cancer Institute
NSABP B-43 / Breast Adjuvant
A Phase III Intergroup CLL Study of Asymptomatic Patients With Untreated Chronic Lymphocytic Leukemia Randomized to Early Intervention Versus Observation With Later Treatment in the High Risk Genetic Subset With IGVH Unmutated Disease
Offered at: Providence Cancer Institute
C10501 / Leukemia
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission after Primary Induction Failure or Patients over Age 60 in First Remission
Offered at: Providence Cancer Institute
E2902 / Leukemia
A Phase III Randomized Study of R-CHOP v. Dose-adjusted EPOCH-R with Molecular Profiling in Untreated De Novo Diffuse Large B-Cell Lymphomas
Offered at: Providence Cancer Institute
C50303 / Lymphoma
A Phase III Randomized Trial of Imatinib, with or without Bevacizumab (NSC-704865), in Patients with Metastatic or Unresectable Gastrointestinal Stromal Tumors
Offered at: Providence Cancer Institute
S0502 / Gastrointestinal
A Phase III Study of the Addition of Gemtuzumab Ozogamicin (Mylotarg®) Induction Therapy Versus Standard Induction With Daunomycin and Cytosine Arabinoside Followed by Consolidation and Subsequent Randomization to Post-Consolidation Therapy With Gemtuzumab Ozogamicin (Mylotarg®) or No Additional Therapy for Patients Under Age 61 With Previously Untreated De Novo Acute Myeloid Leukemia (AML)
Offered at: Providence Cancer Institute
S0106 / Leukemia
A Phase III Study of Weekly Carboplatin With and Without Phenoxodiol in Patients With Platinum-Resistant, Recurrent Epithelial Ovarian Cancer
Offered at: Providence Cancer Institute
Ovature / Ovarian
A Phase III Trial Evaluating the Addition of Cetuximab to Paclitaxel, Cisplatin, and Radiation for Patients With Esophageal Cancer Who Are Treated Without Surgery
Offered at: Providence Cancer Institute
RTOG 0436 / Esophageal
A Phase III Trial of Irinotecan/5-FU/Leucovorin or Oxaliplatin/5-FU/Leucovorin with Bevacizumab, or Cetuximab (C225), or with Combination of Bevacizumab and Cetuximab for Patients with Untreated Metastatic Adenocarcinoma of the Colon or Rectum
Offered at: Providence Cancer Institute
CALGB 80405 / Gastrointestinal
A Pilot (Phase I) Study of Weekly Docetaxel and Cetuximab Chemoradiation for Poor Risk Stage III Non-Small Cell Lung Cancer
Offered at: Providence Cancer Institute
S0429 / Lung Non-Small Cell
A randomised, multi-centre, open-label, phase III study of adjuvant lapatinib, trastuzumab, their sequence and their combination in patients with HER2/ErbB2 positive primary breast cancer
Offered at: Providence Cancer Institute
N063D/ALTTO/BIG2-06 / Breast Cancer
A Randomized Phase II Trial of Azacitidine With or Without the Histone Deacetylase Inhibitor MS-275 for the Treatment of Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia (Dysplastic Type), and Acute Myeloid Leukemia With Multilineage Dysplasia
Offered at: Providence Cancer Institute
E1905 / Leukemia
A randomized phase III double-blind placebo controlled trial of first line chemotherapy and trastuzumab with or without bevacizumab for patients with HER-2/NEU over-expressing metastatic breast cancer
Offered at: Providence Cancer Institute
E1105 / Breast Adjuvant
A randomized phase III double-blind placebo controlled trial of first line chemotherapy and trastuzumab with or without bevacizumab for patients with HER-2/NEU over-expressing metastatic breast cancer
Offered at: Providence Cancer Institute
E1105 / Breast Adjuvant
A randomized phase III double-blind placebo controlled trial of first line chemotherapy and trastuzumab with or without bevacizumab for patients with HER-2/NEU over-expressing metastatic breast cancer
Offered at: Providence Cancer Institute
E1105 / Breast Cancer
A Randomized Phase III Study Comparing 5-FU, Leucovorin and Oxaliplatin versus 5-FU, Leucovorin, Oxaliplatin and Bevacizumab in Patients with Stage II Colon Cancer at High Risk for Recurrence to Determine Prospectively the Prognostic Value of Molecular Markers
Offered at: Providence Cancer Institute
ECOG 5202 / Gastrointestinal
A Randomized Phase III Study of Conventional Whole Breast Irradiation (WBI) Versus Partial Breast Irradiation (PBI) for Women with Stage 0,I or II Breast Cancer
Offered at: Providence Cancer Institute
NSABP B-39 / Breast Cancer
A Randomized Phase III Trial of Neoadjuvant Therapy in Patients with Palpable and Operable Breast Cancer Evaluating the Effect on Pathologic Complete Response (pCR) of Adding Capecitabine or Gemcitabine to Docetaxel when Administered Before AC with or without Bevacizumab and Correlative Science Studies Attempting to Identify Predictors of High Likelihood for pCR with Each of the Regimens
Offered at: Providence Cancer Institute
B-40 / Breast Cancer
A Randomized Phase III Trial of Oxaliplatin (OXAL) Plus 5-Fluorouracil (5-FU)/Leucovorin (CF) with or without Cetuximab (C225) after Curative Resection for Patients with Stage III Colon Cancer
Offered at: Providence Cancer Institute
N0147 / Gastrointestinal
A Randomized Phase III Trial to Test the Strategy of Changing Therapy Versus Maintaining Therapy for Metastatic Breast Cancer Patients who Have Elevated Circulating Tumor Cell Levels at First Follow-Up Assessment
Offered at: Providence Cancer Institute
S0500 / Breast Cancer
ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma
Offered at: Providence Cancer Institute
E2805 / Renal
Bortezomib, Melphalan, and Dexamethasone in Treating Patients With Primary Amyloidosis or Light Chain Deposition Disease
Offered at: Providence Cancer Institute
2006-132 / Multiple Myeloma
CHAARTED: ChemoHormonal Therapy versus Androgen Ablation Randomized Trial for Extensive Disease in Prostate Cancer
Offered at: Providence Cancer Institute
E3805 / Prostate
Evaluation of CHOP Plus Involved Field Radiotherapy followed by Yttrium-90 Ibritumomab Tiuxetan for Stages I, IE and non-bulky Stages II and IIE, CD20 Positive, High-risk Localized, Aggressive Histologies of Non-Hodgkin's Lymphoma, Phase II
Offered at: Providence Cancer Institute
S0313 / Lymphoma
Molecular Epidemiology Case-Series Study of Non-Small Cell Lung Cancer in Smoking and Non-Smoking Women and Men
Offered at: Providence Cancer Institute
S0424 / Screening/Prevention
Molecular Epidemiology Case-Series Study of Non-Small Cell Lung Cancer in Smoking and Non-Smoking Women and Men
Offered at: Providence Cancer Institute
SWOG 0424 / Lung Non-Small Cell
PHASE II STUDY OF PXD101 (NSC-726630) IN RELAPSED AND REFRACTORY AGGRESSIVE
Offered at: Providence Cancer Institute
0520 / Lymphoma
Phase II Trial Of Carboplatin/Gemcitabine Plus Bevacizumab In Advanced Non-Small Cell Lung Cancer
Offered at: Providence Cancer Institute
AVF3121s / Lung Non-Small Cell
Phase II Trial of Pemetrexed in Patients with Selected Stage IIIB and IV Bronchioloalveolar Carcinoma (BAC)
Offered at: Providence Cancer Institute
S0526 / Bronchioloalveolar CA
Phase III Comparison of Thoracic Radiotherapy Regimens in Patients with Limited Small Cell Lung Cancer also Receiving Cisplatin and Etoposide
Offered at: Providence Cancer Institute
CALGB 30610 / Lung
PHASE III RANDOMIZED TRIAL OF ANASTROZOLE VERSUS ANASTROZOLE AND FULVESTRANT AS FIRST LINE THERAPY FOR POST MENOPAUSAL WOMEN WITH METASTATIC BREAST CANCER
Offered at: Providence Cancer Institute
S0226 / Breast Cancer
Phase III Study of Docetaxel and Atrasentan versus Docetaxel and Placebo for Patients with Advanced Hormone Refractory Prostate Cancer
Offered at: Providence Cancer Institute
S0421 / Prostate
Phase III Trial of Continuous Schedule AC + G Vs. Q 2 Week Schedule AC, Followed by Paclitaxel Given Either Every 2 weeks or Weekly for 12 Weeks as Post-Operative Adjuvant Therapy in Node-Positive or High -Risk Node Negative Breast Cancer
Offered at: Providence Cancer Institute
S0221 / Breast Cancer
Program for the Assessment of Clinical Cancer Tests (PACCT-1)
Offered at: Providence Cancer Institute
TAILORx / Breast Cancer
Protocol EC-FV-03: A Phase II Study of EC145 in Patients With Progressive Adenocarcinoma of the Lung
Offered at: Providence Cancer Institute
EC-FV-03 / Lung Non-Small Cell
Randomized Phase 3b Study of Three Treatment Regimens in Subjects With Previously Untreated Multiple Myeloma Who Are Not Considered Candidates for High-Dose Chemotherapy and Autologous Stem Cell Transplantation: VELCADE,Thalidomide, and Dexamethasone Versus VELCADE and Dexamethasone Versus VELCADE, Melphalan, and Prednisone
Offered at: Providence Cancer Institute
C05009 / Multiple Myeloma
Randomized, Phase III, Double-Blind Placebo-Controlled Trial of Sunitinib (NSC #736511, IND #74019) as Maintenance Therapy in Non-Progressing Patients Following an Initial Four Cycles of Platinum-Based Combination Chemotherapy in Advanced, Stage IIIB / IV Non-Small Cell Lung Cancer
Offered at: Providence Cancer Institute
CALGB 30607 / Ancillary Trials
The BeST Trial: A Randomized Phase II Study of VEGF, RAF Kinase, and mTOR Combination Targeted Therapy (CTT) With Bevacizumab, Sorafenib and Temsirolimus in Advanced Renal Cell Carcinoma [BeST]
Offered at: Providence Cancer Institute
ECOG 2804 / Renal
A phase III randomized study of 5-fluorouracil, mitomycin-C and radiotherapy versus 5-fluorouracil, cisplatin and radiotherapy in carcinoma of the anal canal.
Offered at: Providence Cancer Institute
RTOG 9811 / Colon
A Phase III Trial of Carboplatin and Paclitaxel Plus Placebo vs. Carboplatin and Paclitaxel Plus Concurrent Bevacixumab Followed by Placebo, vs. Carboplatin and Paclitaxel plus Concurrent and Extended Bevacizumab, in Women with Newly Diagnosed, Previously Untreated, Stage III (Suboptimal) and All Stage IV Epithelial Ovarian and Primary Peritoneal Cancer.
Offered at: Providence Cancer Institute
GOG 0218 / GYN-Ovarian
A Phase III, Randomized Trial of Weekly Cisplatin and Radiation versus Cisplatin and Tirapazamine and Radition in Stage IB2, IIA, IIB, IIIB, or IVA Cervical Carcinoma limited to the Pelvis
Offered at: Providence Cancer Institute
GOG-0219 / GYN-Ovarian
A Randomized Phase III Trial of Concurrent Accelerated Radiation and Cisplatin Versus Concurrent Accelerated Radiation, Cisplatin and Cetuximab (C225) [Followed by Surgery for Selected Patients] for Stage III and IV Head and Neck Carcinomas.
Offered at: Providence Cancer Institute
RTOG 0522 / Head and Neck
A Randomized Phase III Trial of Doxorubicin/Cisplatin/Paclitaxel and G-CSF versus Carboplatin/Paclitaxel in Patients with Stage III & IV or Recurrent Endometrial Cancer
Offered at: Providence Cancer Institute
GOG-0209 / GYN-Ovarian
Central Lymphoma Repository Tissue Procurement Protocol for Relapse or Recurrent Disease, Ancillary.
Offered at: Providence Cancer Institute
SWOG 9245 / Ancillary Trials
Central Lymphoma Serum Repository Protocol.
Offered at: Providence Cancer Institute
SWOG 8947 / Ancillary Trials
Cytogenetic Studies in Leukemia Patients.
Offered at: Providence Cancer Institute
SWOG 9007 / Ancillary Trials
Prospective, longitudinal, multi-center, descriptive registry of patients receiving therapy other than surgical resction alone for newly diagnosed head and neck carcinoma
Offered at: Providence Cancer Institute
Lohran's Registry / Head and Neck
